

July 20, 2025

DCS-CRD BSE Limited First Floor, New Trade Wing Rotunda Building, Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai 400001 Fax No.2272 3121/2037/2039 Stock Code: 543213	Listing Compliance National Stock Exchange of India Limited Exchange Plaza, 5 th Floor Plot No. C/1, 'G' Block, Bandra- Kurla Complex Bandra East Mumbai 400051 Fax No.2659 8237/8238 Stock Code: ROSSARI
---	---

Dear Sir/Madam,

Subject.: Q1 FY26 Press Release

Please find enclosed a copy of the Press Release for the Quarter ended June 30, 2025.

The same may please be taken on record and suitably disseminated to all concerned.

Thanking you,

Yours Sincerely,
For Rossari Biotech Limited



Parul Gupta
Head - Company Secretary & Legal
Membership No.: A38895

Encl.: as above

ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001:2015 Certified Company) (CIN: L24100MH2009PLC194818)

Regd. Office: Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (West), Mumbai - 400079, Maharashtra, India. T: +91-22-6123 3800

Factory : Plot No. 10 & 11, Survey No. 90/1/10/ & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. T: 0260-669 3000
: Plot No. D3/24/3, Opposite Yokohama Tyre, Phase III, G.I.D.C Dahej, Village Galenda, Taluka Vagra, Bharuch-Gujarat - 392130, India. T: +91 2641-661621

 info@rossari.com

 www.rossari.com



Rossari Biotech Limited

Corporate Office: Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom,
Vikhroli (West), Mumbai – 400079, Maharashtra, India

Rossari Biotech announces Q1 FY26 results

Q1 FY26

Revenues at Rs. 543.7 Cr, up 11% YoY
EBITDA at Rs. 67.9 Cr, up 4.6% YoY
PAT at Rs. 33.6 Cr, down -3.7% YoY

Mumbai, July 19, 2025: Rossari Biotech Limited (Rossari), a Specialty-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries, has announced its financial results for the quarter ended June 30, 2025.

Consolidated: Q1 FY26 performance overview compared with Q1 FY25

- Revenue from operations grew 11% to Rs. 543.7 crore as compared to Rs. 489.7 crore
- EBITDA improved by 4.6% to Rs. 67.9 crore from Rs. 64.9 crore
 - o EBITDA margin at 12.5% as against 13.3%
- PAT reduced by 3.7% to Rs. 33.6 crore from Rs. 34.9 crore
- EPS (Diluted) stood at Rs. 6.1* as against Rs. 6.3*

Standalone: Q1 FY26 performance overview compared with Q1 FY25

- Revenue from operations stood at Rs. 365.8 crore as against Rs. 300.7 crore, up 21.6%
- EBITDA increased by 10.3% to Rs. 43.9 crore as against Rs. 39.8 crore
 - o EBITDA margin at 12.0% as against 13.2%
- PAT higher by 7.8% to Rs. 26.2 crore as against Rs. 24.3 crore
- EPS (Diluted) stood at Rs. 4.7* as against Rs. 4.4*

Note:

- 1) All figures, unless mentioned otherwise, are on a consolidated basis
- 2) * EPS not annualized

Commenting on the performance, in a joint statement, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, said

"We delivered a steady performance in Q1 FY26, with topline growth driven by strong momentum in our HPPC and AHN segments. Despite a challenging and evolving operating environment, our core businesses continued to demonstrate resilience. Though our export business was lower compared to the last quarter, it has shown healthy growth over the last year. While overall growth remained healthy, we are confident that our continued efficiency initiatives and focused efforts on optimising the product mix will continue to drive growth over the coming quarters.

The HPPC and AHN divisions achieved a healthy growth of 16% and 12% respectively, reflecting the dedicated efforts of our team in a challenging operating environment. We continue to expand our customer base which is significantly contributing to our growth story. The HPPC segment remained the primary growth driver, supported by deeper market penetration and traction across agrochemicals, personal care, institutional and consumer business.

Our ongoing capacity expansion projects across verticals are progressing in a phased manner, with commissioning scheduled over the coming quarters. These strategic investments are aimed at enhancing manufacturing capabilities, improve supply chain agility, and strengthen our responsiveness to high-growth sectors such as personal care, agrochemicals, oil & gas and pharma. We believe these expansions will play a pivotal role in unlocking meaningful value and driving the next phase of our growth journey.

Looking ahead, we remain committed to execution excellence, customer-led innovation, and sustainable value creation. Supported by a robust balance sheet, a strong R&D foundation, and our ongoing capacity expansion initiatives, we are well-positioned to navigate near-term challenges and deliver consistent, profitable growth for all stakeholders."

Key Developments

Update on Capacity Expansion Projects

- Ongoing expansions across the group are progressing in a phased manner, with commissioning over the next few quarters
- Projects aimed at enhancing manufacturing capabilities, improving supply chain agility, and strengthening presence across high-growth sectors
- Expected to drive growth from FY27 onwards as utilisation levels ramp up

Note: Home, Personal Care and Performance Chemicals (HPPC); Textile Specialty Chemicals (TSC); Animal Health and Nutrition (AHN)

< Ends >

About Rossari Biotech Limited:

Rossari Biotech Limited (Rossari) (BSE: 543213, NSE: ROSSARI), is a Speciality-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries. Headquartered at Mumbai, India, the Company operates strategically located manufacturing facilities at Silvassa and Dahej. The Company offers tailor-made solutions for Home, Personal Care and Performance chemicals (HPPC), Textile speciality chemicals and Animal Health and Nutrition (AHN). With differentiated product offerings, Rossari caters to an array of applications across FMCG, Home care, Industrial Cleaning, Personal Care, Textile Speciality Chemicals, Performance Chemicals, the Animal Health and Nutrition and Pet Care businesses. The Company has an extensive and a dedicated network of distributors spread all over India.

For more information, please visit www.rossari.com OR contact:

Ketan Sablok

Rossari Biotech Limited

Tel: +91 22 6123 3800

Email: ketan.sablok@rossari.com

Anoop Poojari / Mitesh Jain

CDR India

Tel: +91 98330 90434 / 96194 44691

Email: anoop@cdr-india.com /
mitesh@cdr-india.com

DISCLAIMER:

Certain statements and opinions with respect to the anticipated future performance of Rossari Biotech Limited in the press release ("forward-looking statements"), which reflect various assumptions concerning the strategies, objectives and anticipated results may or may not prove to be correct. Such forward-looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These include, among other factors, changes in economic, political, regulatory, business or other market conditions. Such forward-looking statements only speak as at the date the press release is provided to the recipient and Rossari Biotech Limited is not under any obligation to update or revise such forward-looking statements to reflect new events or circumstances. No representation or warranty (whether express or implied) is given in respect of any information in this press release or that this press release is suitable for the recipient's purposes. The delivery of this press release does not imply that the information herein is correct as at any time subsequent to the date hereof and Rossari Biotech Limited has no obligation whatsoever to update any of the information or the conclusions contained herein or to correct any inaccuracies which may become apparent subsequent to the date hereof.